Navigation Links
Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

NATICK, Mass., Nov. 16, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin America.  The novel device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin.  The WATCHMAN LAA Closure Device is intended to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation.  The first patient implants were performed by Bernardo Caicedo, M.D., Interventional Cardiologist, at Angiografia de Occidente in Cali, Colombia.

Atrial fibrillation, which affects approximately 15 million patients worldwide, is a disorder that disrupts the heart's ability to beat regularly and pump blood efficiently.  Patients in atrial fibrillation are at greater risk for stroke due to the formation and migration of clots in the left atrial appendage.  Anticoagulants such as warfarin have traditionally been the only therapy for reducing stroke risk in these patients.  Boston Scientific's WATCHMAN device is intended to be an alternative to long-term anticoagulation.  It is designed to close the LAA, thereby preventing clots within the appendage from being dislodged into the bloodstream.  

"I am excited to be part of the first patient implants of the WATCHMAN device in Latin America," said Dr. Caicedo.  "The percutaneously delivered device promises to offer a safe and effective alternative for atrial fibrillation patients who cannot take long-term oral anticoagulants and have limited options to reduce their stroke risk.  It incorporates a pre-loaded device that is both repositionable and retrievable to enhance its ease of use."

The WATCHMAN Device is the most clinically studied product of its kind currently available.  In the multi-center, randomized PROTECT AF clinical trial, it proved to be non-inferior to warfarin and demonstrated a 38 percent relative risk reduction for a combined measure of stroke, cardiovascular death and systemic embolism compared to long-term warfarin therapy in 800 patients.  The study also showed a 29 percent relative risk reduction in all stroke and a 90 percent relative risk reduction in hemorrhagic stroke compared to warfarin. Nearly 1,800 patients have now been recruited in WATCHMAN clinical trials with more than 2,700 patient-years of follow-up.  The WATCHMAN device is CE Marked and was commercialized outside the United States in 2009."The WATCHMAN device has been well received in many CE Mark countries and we look forward to beginning commercial launch in select Latin American markets this quarter," said Hank Kucheman, Chief Executive Officer for Boston Scientific.  "We are pleased to bring this technology to more customers and their patients worldwide."

Boston Scientific is currently enrolling U.S. patients in the PREVAIL study, a confirmatory study designed to gain Food and Drug Administration approval.  Enrollment is expected to be completed in the first quarter of 2012.  In the U.S., the WATCHMAN device is an investigational device, limited by applicable law to investigational use and not available for sale.  The device was developed by Atritech, which Boston Scientific acquired in March 2011.  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit:  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, markets for our products, product performance and acceptance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Eric Olson336-293-4393 (office)Media RelationsBoston Scientific Corporationeric.olson@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
(Date:10/13/2015)...  EndoChoice Holdings, Inc. (NYSE:  GI) announced today that ... on Thursday, November 5, 2015 before the market open. ... . --> EndoChoice will hold ... 9:00 a.m. ET to discuss the results. The dial-in ... 317-5469 for international callers. A live webcast of the ...
(Date:10/13/2015)... Regen BioPharma, Inc. , ... Harry Lander , PhD as its new president.  Dr. Lander ... David Koos as Regen BioPharma prepares to take the ... --> Regen BioPharma, Inc. , (OTCBB: RGBP, ... , PhD as its new president.  Dr. Lander will work ...
(Date:10/13/2015)... 13, 2015 China Jo-Jo Drugstores, ... Jo-Jo "), a leading China-based retail, wholesale and online ... own online and retail pharmacies, announced preliminary half year ... online pharmacy through , growing 438% year ... 25%. China Jo-Jo,s online sales ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, ... sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take place ... NAVUG Summit are independent user conferences designed and led by users to provide ...
(Date:10/13/2015)... ... October 13, 2015 , ... Element Blue ™, a ... new company, RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers ... fully-managed approach for customers requiring sensor hardware for critical data environments. , RightSensor™, ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded ... See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB 3.0 interface ... e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 ...
(Date:10/13/2015)... Tenn. (PRWEB) , ... October 13, 2015 , ... A ... and that’s why SmileCareClub , the leading remote invisible aligner system, has joined ... who would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will ...
Breaking Medicine News(10 mins):